FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tom Wiklund

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Co-author Network

Publications

TOP 3
Mariann Iiristo; Tom Wiklund; Nils Wilking; Jonas Bergh; Yvonne Brandberg
Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels.
Nils Wilking; Elisabet Lidbrink; Tom Wiklund; Bjørn Erikstein; Henrik Lindman; Per-Uno Malmstrom; Pirkko Kellokumpu-Lehtinen; Nils-Olof Bengtsson; G Söderlund; Gun Anker; Erik Wist; S Ottosson; E Salminen; P Ljungman; Harald Holte; J Nilsson; Carl Blomqvist; Jonas Bergh
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.
Pirkko Kellokumpu-Lehtinen; Jonas Bergh; E Salminen; Tom Wiklund; Saara Lehtinen; Pasi Aronen; Harri Sintonen
Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tom Wiklund (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Mariann Iiristo; Tom Wiklund; Nils Wilking; Jonas Bergh; Yvonne Brandberg
Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels.
Acta oncologica (Stockholm, Sweden) 2011;50(3):338-43.
2007: Nils Wilking; Elisabet Lidbrink; Tom Wiklund; Bjørn Erikstein; Henrik Lindman; Per-Uno Malmstrom; Pirkko Kellokumpu-Lehtinen; Nils-Olof Bengtsson; G Söderlund; Gun Anker; Erik Wist; S Ottosson; E Salminen; P Ljungman; Harald Holte; J Nilsson; Carl Blomqvist; Jonas Bergh
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):694-700.
2007: Pirkko Kellokumpu-Lehtinen; Jonas Bergh; E Salminen; Tom Wiklund; Saara Lehtinen; Pasi Aronen; Harri Sintonen
Cost-effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy - results from a randomized study.
Acta oncologica (Stockholm, Sweden) 2007;46(2):146-52.
2006: Seija Grénman; Tom Wiklund; Jyrki Jalkanen; Tapio Kuoppala; Johanna Mäenpää; Arja Kuronen; Arto Leminen; Ulla Puistola; Päivi Vuolo-Merilä; Tuula Salmi; Maarit Vuento; Merja Yliskoski; Maija Itälä; Hans Helenius; Heikki Joensuu; Pentti Lehtovirta
A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study.
European journal of cancer (Oxford, England : 1990) 2006;42(14):2196-9.
2006: Mervi Laakso; Minna Tanner; Jonas Nilsson; Tom Wiklund; Bjørn Erikstein; Pirkko Kellokumpu-Lehtinen; Per Malmström; Nils Wilking; Jonas Bergh; Jorma Isola
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4185-91.
2006: Minna Tanner; Jorma Isola; Tom Wiklund; Bjørn Erikstein; Pirkko Kellokumpu-Lehtinen; Per Malmström; Nils Wilking; Jonas Nilsson; Jonas Bergh
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2428-36.
2003: Yvonne Brandberg; Helena Michelson; Bo Nilsson; Christina Bolund; Bjørn Erikstein; Paivi Hietanen; Stein Kaasa; Jonas Nilsson; Tom Wiklund; Nils Wilking; Jonas Bergh
Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(19):3659-64.
2003: Sigbjørn Smeland; C Müller; Thor A Alvegard; Tom Wiklund; Thomas Wiebe; O Björk; Anna E Stenwig; Helena Willén; T Holmström; Gunnar Follerås; Otte Brosjö; Aarne Kivioja; K Jonsson; OR Monge; Gunnar Saeter
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.
European journal of cancer (Oxford, England : 1990) 2003;39(4):488-94.
2002: Riikka Oinonen; Esa Jantunen; Maija Itälä; Tuula Lehtinen; Outi Kuittinen; Kaarle Franssila; Tom Wiklund; Erkki Elonen
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Leukemia & lymphoma 2002;43(6):1229-37.
2002: Micaela Hernberg; Pekka Virkkunen; Paula Maasilta; Jani Keyriläinen; Carl Blomqvist; Jonas Bergh; Tom Wiklund
Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study.
International journal of radiation oncology, biology, physics 2002;52(1):128-36.
2001: Maija Tarkkanen; Tom Wiklund; Martti Virolainen; Marcelo L Larramendy; N Mandahl; F Mertens; Carl Blomqvist; Erkki Tukiainen; Markku Miettinen; A I Elomaa; Y S Knuutila
Comparative genomic hybridization of postirradiation sarcomas.
Cancer 2001;92(7):1992-8.
2001: A Harjunpää; Tom Wiklund; Juhani Collan; Rita Janes; J Rosenberg; D Lee; A Grillo-López; Seppo Meri
Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma.
Leukemia & lymphoma 2001;42(4):731-8.
2001: K S Hall; Tom Wiklund; Bjørn Erikstein; Harald Holte; Gunnar Kvalheim; H H Sommer; A Andersen; Eva Skovlund; Jonas Bergh; C Hall
Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients.
Breast cancer research and treatment 2001;67(3):235-44.
2001: Henrik C F Bauer; Clement S Trovik; Thor A Alvegård; Orjan Berlin; Martin Erlanson; Pelle Gustafson; R Klepp; Torgil R Möller; Anders Rydholm; Gunnar Saeter; O Wahlström; Tom Wiklund
Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register.
Acta orthopaedica Scandinavica 2001;72(2):150-9.
2001: Sanna-Mari Maula; Riikka Huuhtanen; Carl Blomqvist; Tom Wiklund; P Laurila; R Ristamäki
The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas.
British journal of cancer 2001;84(2):244-52.
2000: Jonas Bergh; Tom Wiklund; Bjørn Erikstein; Elisabet Lidbrink; Henrik Lindman; Per Malmström; Pirkko Kellokumpu-Lehtinen; Nils-Olof Bengtsson; G Söderlund; Gun Anker; Erik Wist; S Ottosson; E Salminen; P Ljungman; Harald Holte; J Nilsson; Carl Blomqvist; Nils Wilking
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Lancet 2000;356(9239):1384-91.
2000: T Erselcan; Kalevi Kairemo; Tom Wiklund; Micaela Hernberg; Carl Blomqvist; Mikko Tenhunen; Jonas Bergh; Heikki Joensuu
Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.
British journal of cancer 2000;82(4):777-81.
1999: Riikka Huuhtanen; Tom Wiklund; Carl Blomqvist; Tom Böhling; Martti Virolainen; B Tribukait; Leif C Andersson
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.
British journal of cancer 1999;81(6):1017-21.
1999: Maija Tarkkanen; Riikka Huuhtanen; Martti Virolainen; Tom Wiklund; Sirpa Asko-Seljavaara; Erkki Tukiainen; M Lepäntalo; Inkeri Elomaa; Sakari Knuutila
Comparison of genetic changes in primary sarcomas and their pulmonary metastases.
Genes, chromosomes & cancer 1999;25(4):323-31.
1999: Riikka Huuhtanen; Carl Blomqvist; Tom Böhling; Tom Wiklund; Erkki Tukiainen; Martti Virolainen; B Tribukait; Leif C Andersson
Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness.
Cancer research 1999;59(12):2885-90.
1999: Gunnar Saeter; Thomas Wiebe; Tom Wiklund; OR Monge; Y Wahlqvist; K Engström; Erik Forestier; T Holmström; Anna E Stenwig; Helena Willén; Otte Brosjö; Gunnar Follerås; Thor A Alvegård; Hans Strander
Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.
Acta orthopaedica Scandinavica. Supplementum 1999;285():74-82.
1999: Jan-Olof Fernberg; Tom Wiklund; OR Monge; K S Hall; Gunnar Saeter; Thor A Alvegård; Hans Strander
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
Acta orthopaedica Scandinavica. Supplementum 1999;285():62-8.
1999: Henrik C F Bauer; Thor A Alvegård; Orjan Berlin; Martin Erlanson; Pelle Gustafson; Aarne Kivioja; R Klepp; Tuula Lehtinen; P Lindholm; Torgil R Möller; Anders Rydholm; Gunnar Saeter; Clement S Trovik; O Wahlström; Tom Wiklund
The Scandinavian Sarcoma Group Register.
Acta orthopaedica Scandinavica. Supplementum 1999;285():41-4.
1999: Riikka Huuhtanen; Carl Blomqvist; Tom Wiklund; Tom Böhling; Martti Virolainen; Erkki Tukiainen; B Tribukait; Leif C Andersson
Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma.
British journal of cancer 1999;79(5-6):945-51.
1999: Henrik Lindman; Tom Wiklund; Harald Holte; P Ljungman; Carl Blomqvist; Gunnar Kvalheim; M Bengtsson; Mattias Höglund; Nils Wilking; Jonas Bergh
FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group.
Acta oncologica (Stockholm, Sweden) 1999;38(2):239-45.
1998: Jonas Bergh; Tom Wiklund; Bjørn Erikstein; Tommy Fornander; Nils-Olof Bengtsson; Per Malmström; Pirkko Kellokumpu-Lehtinen; Gun Anker; H Bennmarker; Nils Wilking
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):403-11.
1997: Mikael Kajanti; Carl Blomqvist; Hannu Lehtonen; Mauri Kouri; Tom Wiklund; Lars R Holsti
Biweekly dose escalation in curative accelerated hyperfractionation for advanced head and neck cancer: a feasibility study.
International journal of radiation oncology, biology, physics 1997;39(4):837-40.
1997: J Szymanska; Martti Virolainen; Maija Tarkkanen; Tom Wiklund; Sirpa Asko-Seljavaara; Erkki Tukiainen; Inkeri Elomaa; Carl Blomqvist; Sakari Knuutila
Overrepresentation of 1q21-23 and 12q13-21 in lipoma-like liposarcomas but not in benign lipomas: a comparative genomic hybridization study.
Cancer genetics and cytogenetics 1997;99(1):14-8.
1997: Marcelo L Larramendy; Maija Tarkkanen; Carl Blomqvist; Martti Virolainen; Tom Wiklund; Sirpa Asko-Seljavaara; Inkeri Elomaa; Sakari Knuutila
Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker.
The American journal of pathology 1997;151(4):1153-61.
1997: Tom Wiklund; Gunnar Saeter; Hans Strander; Thor A Alvegård; Carl Blomqvist
The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience.
European journal of cancer (Oxford, England : 1990) 1997;33(3):357-61.
1996: H Mäenpää; Carl Blomqvist; Tom Wiklund; T Lehtonen; Inkeri Elomaa
Results of treatment in testicular nonseminoma.
Annals of medicine 1996;28(4):311-4.
1996: I Ilveskoski; UM Saarinen; Tom Wiklund; Mikko Perkkiö; Toivo T Salmi; Marjatta Lanning; Anne Mäkipernaa; Helena Pihko
Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.
Medical and pediatric oncology 1996;27(1):26-31.
1996: I Ilveskoski; Helena Pihko; Tom Wiklund; S Lamminranta; Mikko Perkkiö; Anne Mäkipernaa; Toivo T Salmi; Marjatta Lanning; UM Saarinen
Neuropsychologic late effects in children with malignant brain tumors treated with surgery, radiotherapy and "8 in 1" chemotherapy.
Neuropediatrics 1996;27(3):124-9.
1996: Carl Blomqvist; Riikka Huuhtanen; Y Pan; Tom Wiklund; Maija Tarkkanen; Martti Virolainen; B Tribukait
Growth rate of lung metastases and S-phase fraction as determined by flow cytometry from the primary tumour in 25 patients with bone or soft-tissue sarcomas.
British journal of cancer 1996;73(12):1556-9.
1996: Riikka Huuhtanen; Carl Blomqvist; Tom Wiklund; Martti Virolainen; A I Elomaa; Y Pan; B Tribukait
S-phase fraction of 155 soft tissue sarcomas: correlation with clinical outcome.
Cancer 1996;77(9):1815-22.
1996: J Szymanska; Maija Tarkkanen; Tom Wiklund; Martti Virolainen; Carl Blomqvist; Sirpa Asko-Seljavaara; Erkki Tukiainen; Inkeri Elomaa; Sakari Knuutila
Gains and losses of DNA sequences in liposarcomas evaluated by comparative genomic hybridization.
Genes, chromosomes & cancer 1996;15(2):89-94.
1996: Tom Wiklund; Riikka Huuhtanen; Carl Blomqvist; Erkki Tukiainen; Martti Virolainen; Pekka Virkkunen; Sirpa Asko-Seljavaara; J M Björkenheim; Inkeri Elomaa
The importance of a multidisciplinary group in the treatment of soft tissue sarcomas.
European journal of cancer (Oxford, England : 1990) 1996;32A(2):269-73.
1996: J Szymanska; Maija Tarkkanen; Tom Wiklund; Martti Virolainen; Carl Blomqvist; Sirpa Asko-Seljavaara; Erkki Tukiainen; Inkeri Elomaa; Sakari Knuutila
Cytogenetic study of extraskeletal mesenchymal chondrosarcoma. A case report.
Cancer genetics and cytogenetics 1996;86(2):170-3.
1996: Tom Wiklund; Carl Blomqvist; Leila Risteli; Juha Risteli; Erkki O Karaharju; Inkeri Elomaa
Type I and type III collagen metabolites in adult osteosarcoma patients.
British journal of cancer 1996;73(1):106-9.
1995: J Szymanska; Maija Tarkkanen; Tom Wiklund; Martti Virolainen; Carl Blomqvist; Sirpa Asko-Seljavaara; Erkki Tukiainen; Inkeri Elomaa; Sakari Knuutila
A cytogenetic study of malignant fibrous histiocytoma.
Cancer genetics and cytogenetics 1995;85(2):91-6.
1995: Carl Blomqvist; Tom Wiklund; M Pajunen; Martti Virolainen; Inkeri Elomaa
Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma.
Cancer chemotherapy and pharmacology 1995;36(3):263-5.
1994: Maija Tarkkanen; Tom Wiklund; Martti Virolainen; Inkeri Elomaa; Sakari Knuutila
Dedifferentiated chondrosarcoma with t(9;22)(q34;q11-12).
Genes, chromosomes & cancer 1994;9(2):136-40.
1993: Carl Blomqvist; Tom Wiklund; Maija Tarkkanen; Inkeri Elomaa; Martti Virolainen
Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma.
British journal of cancer 1993;68(2):414-7.
1993: Tom Wiklund; Carl Blomqvist; Leila Risteli; Juha Risteli; Inkeri Elomaa
Impact of chemotherapy on collagen metabolism: a study of serum PIIINP (aminoterminal propeptide of type III procollagen) in advanced sarcomas.
Journal of cancer research and clinical oncology 1993;119(3):160-4.
1993: Tom Wiklund; Thor A Alvegård; H T Mouridsen; A Rydholm; Carl Blomqvist
Marginal surgery and postoperative radiotherapy in soft tissue sarcomas. The Scandinavian Sarcoma Group experience.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):306-9.
1992: Tom Wiklund; Inkeri Elomaa; Carl Blomqvist; Leila Risteli; Juha Risteli
Type III collagen metabolism in soft tissue sarcomas.
British journal of cancer 1992;65(2):193-6.
1992: Tom Wiklund; Carl Blomqvist; Martti Virolainen; Inkeri Elomaa
Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
Cancer chemotherapy and pharmacology 1992;30(2):100-4.
1992: Timo Muhonen; Tom Wiklund; Carl Blomqvist; Seppo Pyrhönen
Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate.
European journal of cancer (Oxford, England : 1990) 1992;28A(12):1974-6.
1991: Tom Wiklund; Carl Blomqvist; J Räty; Inkeri Elomaa; P Rissanen; M Miettinen
Postirradiation sarcoma. Analysis of a nationwide cancer registry material.
Cancer 1991;68(3):524-31.
1990: P Appelqvist; M Salmo; P Rissanen; Tom Wiklund
Response of postmastectomy lymphangiosarcoma to radiotherapy: report of four cases.
Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] 1990;166(3):194-8.
1990: Kalevi Kairemo; Tom Wiklund; K Liewendahl; M Miettinen; Jorma Heikkonen; Pekka Virkkunen; Hannu J Aronen; Carl Blomqvist
Imaging of soft-tissue sarcomas with indium-111-labeled monoclonal antimyosin Fab fragments.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(1):23-31.